FORTUNE SHINES ON THE PREPARED AS LIFE SCIENCES SUPPLY CHAIN HEADS
TOWARD DSCSA IMPLEMENTATION DEADLINES
 |
| Sessions at the recent HDMA Management Conference focused on DSCSA implementation |
The Distribution Management Conference organized by the Healthcare
Distribution Management Association (HDMA) this month in San Antonio, TX focused
the event on the current issues and challenges the DSCSA and of Serialization.
Admiral James Stavridis, U.S. Navy (Ret.), and a former NATO
Supreme Commander painted a picture of despair and hope in his presentation
"Beyond the Horizon: 21st Century Global Security and Risk."
Biological, Cyber and conventional terrorist threats raise many questions
about how to effectively navigate our current global situation for a peaceful
and productive future.
The Admiral's presentation reflected the general feeling of apprehension
and uncertainty surrounding the looming deadlines for implementation of the
DSCSA regulations. The new rules affect organizations throughout the
healthcare supply chain requiring coordination not only within companies but
also between different links within the chain to create an effective solution.
Stakes are high because large capital investments are required in
order to plan, implement and manage upgrades to technology, systems and
equipment as well as ongoing training required to conform to the DSCSA
regulations. The combination of significant financial investment for a
transition in which different parties define requirements in different ways is
cause for concern.
The workflow of life sciences 3PL firms including WDSrx demands
the efficient receipt, storage and distribution of pharmaceutical drug products
from their point of manufacture to their final destination. "Our focus is
on serving our clients by satisfying their patients," says WDSrx Marketing
Director Larry Hotz. "WDSrx is compliant with DSCSA regulations and
will implement future rules prior to their implementation deadline."
The ultimate goal of the DSCSA is to produce a safer marketplace
with the ability to track and trace prescription drug products at every stage
of production through delivery. This is an important objective our
industry plans to achieve together as it navigates the current regulatory
landscape.
